Erlotinib in pancreatic cancer patients: do we need more information from the NCIC CTG trial?

J Clin Oncol. 2007 Sep 20;25(27):4320-1; author reply 4321-2. doi: 10.1200/JCO.2007.12.8801.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Clinical Trials as Topic
  • Disease Progression
  • Disease-Free Survival
  • Erlotinib Hydrochloride
  • Humans
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / pathology
  • Prognosis
  • Protein Kinase Inhibitors / therapeutic use*
  • Quinazolines / therapeutic use*
  • Research Design
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Protein Kinase Inhibitors
  • Quinazolines
  • Vascular Endothelial Growth Factor A
  • Erlotinib Hydrochloride